By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

The stock was the top percentage gainer on the Nifty Pharma index, which traded 0.3% higher compared to a 0.8% loss in the ...

Glenmark Pharma's exclusive licensing deal with AbbVie for ISB-2001 could be transformative, offering significant upside ...

Glenmark Pharmaceuticals Ltd's shares soared over 14% after announcing a deal with AbbVie worth up to USD 2 billion. The ...

Ichnos Glenmark Innovation & AbbVie ink exclusive global licensing agreement for ISB 2001: New York Saturday, July 12, 2025, 12:00 Hrs [IST] IGI Therapeutics SA, a wholly owned su ...

Regardless of the bearish sentiment prevailing across the Indian stock market today, Glenmark Pharma shares skyrocketed 16% ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

The shares of the prominent pharmaceutical company broke the upper band, gained up to 15 percent in today's trading session after the company's subsidiary of Ichnos Glenmark Innovation Inc., entered ...

The S&P BSE Sensex also ended lower, falling 0.83% to close at 82,500 points, and registered a weekly loss of over 1.06%.

The investment landscape is shifting as companies show resilience and innovation, prompting investors to reassess portfolios. AbbVie, Boeing, Oracle, and Joby Aviation mentioned as potential ...

Taxpayers required to file ITR-2 or ITR-3 can now download the Excel utilities from the I-T department’s e-filing portal, ...